Scholars LITERATURE

Obesity and Diabetes Research

Short Communication

DOI: https://doi.org/10.47275/2692-0964-107
Volume 1 Issue 2

Cancer and Diabetes: Invited Short Commentary

Arun Kumar R*

Department of Biochemistry & Bioinformatics, GITAM Institute of Science, GITAM University, Visakhapatnam, India

Abstract

The risk of various cancers is increased by diabetes mellitus. The correlation of diabetes with increased prevalence increased development and enhanced cancer aggression has been justified by researchers. Research has improved the association of diabetes among different cancers with the risk of colorectal cancer. Some progress has been made in diagnosis and treatment in recent years, but even today, colorectal remains a big problem for people's health. There is a need for prophylaxis, assessment, and proper care to minimize cancer mortality. The policy-making mechanism needs distressing cancer prognosis factors for beneficial approaches to cancer patients and disease progression. Ultimately, diabetes-specific methods are discussed for various cancers.

Keywords: Diabetes Mellitus; Type 2 Diabetes; Cancer; IGF-I; IGF-II; Metformin HCl

Correspondence to: Arun Kumar R, Department of Biochemistry & Bioinformatics, GITAM Institute of Science, GITAM University, Visakhapatnam, India; E-mail: arunram88@gmail.com

Citation: Arun Kumar R (2020) Cancer and Diabetes: Invited Short Commentary. Obes Diabetes Res, Volume 1:2. 107. DOI: https://doi.org/10.47275/2692-0964-107.

Received: November 25, 2020; **Accepted:** December 22, 2020; **Published:** December 29, 2020

Short Communication

Due to the diabetes risk of tumor stretch might have enhanced, such as pancreas, liver, early gastric, ovarian, prostate, breast, and colorectal cancer. It is one of the world's long-standing communal diseases that affects every segment of society consisting of women, young people, and grown people. Diabetic women are more likely to develop an elevated incidence and mortality rate of colorectal cancer [1]. Diabetes has been linked to a higher risk of colorectal cancer in most, though not all, research. In the colorectum on sex and subsite, there were non-conclusive findings. Evidence from a variety of independent studies has been performed on the interrelation of diabetes with the incidence and morbidity of colorectal cancer to overcome these contradictions. The results support the correlation of diabetes with a greater risk of colorectal cancer in the population [2,3]. People with diabetes have a relative risk of cancer that is around 30 % more than non-diabetic people. The outcomes of epidemiological observational research in Europe and the United States have been clear. The relationship was experienced in both genders and all colorectal sub-areas.

Diabetes mellitus and colorectal cancer are the major causes of illness and transience in the United States and Western nations, as diabetes is predicted to become the biggest cause of mortality in the next 2-3 decades [2,4]. Individuals with diabetes mellitus can form oral tumors and precancerous tumors. In 2015, over 400 million individuals had diabetes, and 17.5 million individuals had cancer worldwide. In the United States, colorectal cancer is the second largest killer. Due to the increasing obesity epidemic, the incidence of diabetes is projected to increase, which may lead to an increase in other cases of colorectal cancer. These results show important factors including hyperinsulinemia or insulin resistance in colorectal cancer. However, although the scientific study was restricted to studies that regulated physical activity and body mass index, the positive interconnection between diabetes and colorectal cancer risk continued.

Close to 16% of the total of women with breast cancer have diabetes [5], and two main medical conditions for t2d, such as late adulthood and obesity, are also linked with breast cancer. The research found that, as opposed to non-diabetics, the risk of pancreatic cancer in people with diabetes is 82 percent higher. Colorectal cancer has the third-largest prevalence of cancer in females and males [6].

Next to lung and breast cancer, it is the third prevalent form of malignancy in the global population, with nearly 0.00124 billion new cases detected in 2008. Diabetes mellitus is now sufficiently confirmed to be an independent factor in sarcoma development [7]. However, the condition is unclear whether the presence of diabetes mellitus is concomitant with the prognosis of cancer patients after cancer. With the prevalence rate of widespread diabetes, notably by those aged 65 and more with the highest cancer risk, a better understanding of relationships may have major implications for healthy living. In several regions of the world, CRC is the worldwide occurrence disease and the fourth most frequently diagnosed mortality disease, with a higher prevalence of duration in men compares to women [8].

Contradictory findings were shown in previous studies of patients with all causes of 8% colorectal cancer and 12% cancer-specific deaths. An earlier systematic analysis of six studies available before October 2008 reported a 32% increase in diabetes-related deaths, plus no pooled estimates of cancer-specific mortality [9]. As diabetes is the third-largest source of non-cancer death in people affected by CRC, diabetes is also closely related to cardiovascular disease, which is the primary cause of non-cancer mortality in colorectal carcinogenic patients. It is important to interpret open life and relapse when defining the supporting part of diabetes in tumor diagnosis.

Estimates of the connotations between diabetes and cancer-specific and all-cause mortality in 2008 were represented in enormous experiments [10]. This data offers a considerable chance to obtain reliable associative estimates. Therefore, the goal of the recent meta-synthesis was to find out whether patients with CRC and diabetes were at greater risk of all-cause and cancer-specific death compared to patients without diabetes. The correlation between diabetes and both disease-free survival and cancer recurrence in CRC patients was also noted across outcomes. A narrative study of 21 papers testifying to total mortality, consisting of 216,981 applicants, revealed an increased probability of all-cause death among 17 percent of colorectal patients associated with diabetes.

The number of patients worldwide have multiplied their numbers from the past 3 years. Around 285 million people were diagnosed in 2010, up to 439 million patients with diabetes by the upcoming 10 years, showing 7.7 percent of mature inhabitants aged around 20-80 [11]. Concerning these factors, the global rivalry between diabetes mellitus pandemics and the rising cancer burden has led to concern about defining the biological and epidemiological link.

The quality of life is affected by type 2 diabetes. In cause considerable neural and vascular impediments, cancer incidence, expansion, and opportunities are correlated with it. A growing number of specialists are considering whether patients living with diabetes in cancer therapy and diabetologists often deal with diabetes in tumor-treated patients. Countervailing hyperinsulinemia leads to hormonal dysfunction, and metabolism also helps to create micro-environments for the development of cancer. Diabetes mellitus can affect the endurance of carcinogenic individuals because of the insulin-stimulated evolution of colorectal cancer cells and inadequate treatment of concurrent patients.

The analysis [12] has addressed the implications of diabetes in the diagnosis of cancer, but since 2013, several studies have revealed detailed estimates of the outcome of the diabetes-colorectal cancer prognosis association, and their results have been accurate. In the overall survival of cancer, for example, diabetes-initiated research showed a significant reduction in the risk of overall cancer survival, and no connection was found in other studies. The findings allowed the relation between them to be precisely evaluated. Estimates of the impact of diabetes mellitus on the CRC prognosis for 5 years of survival and measured effects of diabetes on overall persistence of colon, colorectal and rectal cancer, cancer-specific survival (CSS), cardiovascular disease, and specific survival have been documented in the descriptive analysis [10].

A biologically feasible association between diabetes and colorectal cancer risk has been observed. Elevated blood sugar concentrations are identified in the initial stages of diabetes. Hyperinsulinemia plays a significant role in colorectal carcinogenesis and/or insulin resistance factors. The fundamental relation between diabetes and colon cancer has been suggested to be hyperinsulinemia. Insulin increases cell proliferation via a small path consisting of an insulin receptor or an insulin-like growth factor (IGF)-the direct activation of the I receptor and the main pathway inhibits the binding proteins of the Insulin Growth Factor (especially IGFBP-1 and IGFBP-2), leading to increased insulin growth factor-I. Animal, in vitro, and epidemiological investigations are the main components of insulin and IGF-I in colorectal carcinogenesis [13]. Propagated insulin, C-peptide or IGF-I observational studies have shown that the probability of colorectal cancer in the highest exposure categories is 2-3 times higher than in the minimum exposure categories. Moreover, recent studies suggest that long-term insulin therapy has been associated with a significant cancer risk upsurge in patients diagnosed with diabetes. Other diabetes-related processes involving the risk of colorectal cancer involve fewer passage times in diabetic patients, which can contribute to accelerated colonic mucosal interaction with carcinogenic agents, and higher fecal bile acid concentrations associated with elevated blood glucose and triglyceride levels. Fecal bile acids have been used in animal models to encourage colorectal cancer.

In diabetes mellitus, endogenous hyperinsulinemia can be associated with a greater danger of colorectal cancer. The goal was to determine whether insulin therapy could increase the risk of colorectal cancer in diabetes-positive populations. The danger of colorectal cancer in people with diabetes mellitus [14] is significantly increased by chronic insulin therapy. Colorectal cancer and non-insulin-dependent diabetes mellitus etiology involve westernized diet, living standards, and fatness, which contributes to the belief that colorectal cancer may be stimulated by hyperinsulinemia. Among 75,219 Norwegian men and women, risk relationships, factors of insulin sensitivity and hyperinsulinemia, including body mass index and blood glucose, were investigated. Insulin-dependent flow activation is recognized as a major step in subsidizing various compositions of cancer susceptibility to predictable and guided curative agents, resulting in increased PI3 K/Akt signaling that ultimately stops the death signals generated by chemotherapy and pacifies anti-Epidermal growth factor receptor antibodies against colorectal cancer cells [15]. Scartozzi confirmed abundant IGF-1 expression in KRAS metastatic CRC wildlife patients treated with cetuximab and irinotecan was associated with poor clinical outcomes. Their results showed that the use of the IGF-1 system could enable cancer cells to cure the anti-epidermal growth factor receptor due to an increase in the PI3K-Akt pathway by IGF-1 [11]. Evidence has shown that IGF-1/IGF-1R polymorphisms are possible predictors of cetuximab efficacy in metastatic CRC patients with wild form KRAS [12] in recent decades. Thiazolidinedione and many other peroxisome proliferator-activated receptors and ligands trigger apoptosis of lines H841, A549, abdPC14 of non-small cell lung cancer; arrest G0/G1 process A549 cells; inhibit growth and inductive DNA damage to 153 genes (GADD), and produce primary growth response-1 gene that causes cell death controlled by caspase.

Drugs and Diabetes

Studies showed that metformin inhibits tumor and minimizes cancer risk. In patients with diabetes, the current epidemiological results suggest that metformin reduces cancer deaths [16]. Metformin treatment is associated with a relatively lower risk of colorectal cancer in diabetic patients. Metformin is a relative of isoamylene guanidine and as the first diabetes therapy, promotes lower glucose. Previous research advocate that metformin can indirectly instigate adenosine monophosphate-activated protein kinase, an essential component of adenosine triphosphate and adenosine monophosphate cell balance, be involved in tumor suppression and help to trigger cancer suppressor genes such as LKB1. Subsequent in vitro studies have also shown that metformin prevents the development of tumors [17,18] and eradicates stem cell cancer [10]. Clinical studies agree with these results. Rodent models have shown that metformin can overpower the multiplication of epithelia [18,19]. Accordingly, the capacity of metformin to prevent colon carcinoma division was demonstrated by animal models of colon cancer [18,20]. The likely use of metformin as a new anti-inflammatory medication for colorectal cancer inhibition has been of concern, based on encouraging studies. From this study, we have integrated fully current information and evaluated risk ties for metformin and colorectal cancer in patients with type 2 diabetes. As a result, metformin

therapy was associated with an expected 37 % decrease in the risk of colorectal cancer in people with diabetes [21,22].

Metabolic Pathway

The recurrent association of those diseases, i.e., diabetes and colon cancer, may result from metabolic changes due to high stimulation of Wnt/beta-catenin signaling and receptor-gamma suppression of peroxisome proliferator stimulated response (PPAR gamma). PPAR gamma is down-regulated in both diseases, while the canonical pathway of Wnt/beta-catenin is up-regulated. The canonical Wnt mechanism is triggered in colon cancer, resulting in activation of pyruvate dehydrogenase kinase, and turning off the pyruvate dehydrogenase complex. As a result, a large portion of cytosolic pyruvate is converted into lactate-by-lactate dehydrogenase activation. To extrude lactate from the cell, monocarboxylate transporter-1 activation is used. The mechanism is known as the impact of Warburg. While the canonical prohibition of Wnt/beta-catenin triggers PPAR gamma [23], the PPAR gamma antagonist results in beta-catenin blockage. Clinical research has shown a correlation between diabetes, obesity, and cancer, in particular colon cancer. In contrast to patients who do not have it, patients with type 2 diabetes are 30 percent-40 percent more probable to get colon cancer. The risk of diabetes leads to the possibility of colorectal cancer.

The theory of colon cancer hyperinsulinemia indicates that high levels of free insulin growth factor-1 amplify the development of cells and better modification of cells contributes to carcinogenesis. Increased insulin strength at the start of diabetes is a process of modifying insulin resistance. Cancers, including receptors for A and IGF-1, overexpress insulin receptors. The proliferative properties of both hormones are accompanied by greater insulin/IGF signaling amounts. Cancer development may be increased by abnormally high blood pressure and permanent tenderness. Aerobic glycolysis or the influence of Warburg initiates canonical signal activation. Wnt activates essential metabolic enzymes in both pathologies, such as pyruvate dehydrogenase kinases (PDK). Therefore, there is aerobic glycolysis or Warburg's colon cancer effect. Reduced pyruvate dehydrogenase activity by increased PDK changes metabolic tractability-the ability to control glucose and oxidation of fatty acids. There is debate about oxidation at the level of the pyruvate dehydrogenase complex among glucose and fatty acids, the activity of which is decreased by kinase. Partial deviation from pyruvate to lactate in colon cancer contributes to the synthesis of proteins that are necessary for cell growth and propagation. These significant metabolic changes caused by up-regulated signaling of Wnt/beta-catenin and down-regulated PPAR gamma [23] may partly account for the frequent association of type II diabetes with colon cancer. Insulin tolerance is often a property of diabetes associated with compensatory hyperinsulinemia. By 2010, over 250 million people worldwide will have diabetes mellitus, which will hit 380 million in 20 decades. In advanced studies with a population of over 2.5 million, the approximate risk of emerging colorectal disease in diabetics was around higher than in non-diabetics [14,20, and 24-26]. Because of the severity of type 2 diabetes and the prevalence of cancer, the incidence of the relationship between these two diseases should be investigated and the published evidence reports suggest the pivotal role of diabetes in the development of colorectal malignancy [10,18]. Hence it is important to examine the connection between diabetes and cancer risk. The reported data showed contradictory findings of the relationship between diabetes mellitus with the risk of colorectal cancer. Diabetics are at high risk of carcinogenicity as compared with non-diabetics. Studies of the genome-wide association have identified genes associated with diabetes (e.g., TCF7L2) that may also lead to colorectal cancer.

Conclusion

Epidemiological evidence recommends the prevalence of diabetes-related cancer, some risk factors, and diabetes care. There was also a positive correlation with diabetes, vulva, and vaginal tumors. Subsequent in vitro research indicated that metformin prevents carcinoma proliferation and selectively destroys cancer stem cells. Metformin therapy relatively minimizes the amount of moving glucose among people who are too resistant to insulin and insulin. Some progress has been made in diagnosis and treatment in recent years, but even today, colorectal remains a big problem for people's health. There is a need for prophylaxis, assessment, and proper care to minimize cancer mortality. The policy-making mechanism needs variables that disturb cancer prognosis for beneficial approaches to cancer patients and disease progression. Ultimately, diabetes-specific methods are discussed for various cancers.

References

1. Larsson SC, Giovannucci E, Wolk A (2005) Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 28: 1805-1807.https://doi.org/10.2337/diacare.28.7.1805
2. Szablewski L (2014) Diabetes mellitus: influences on cancer risk. DiabetesMetab Res Rev 30: 543-553.https://doi.org/10.1002/dmrr.2573
3. Yang YX, Hennessy S, Lewis JD (2005) Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 3: 587-594.https://doi.org/10.1016/S1542-3565(05)00152-7
4. Li S, Wang J, Zhang B, Li X, Liu Y (2019) Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J 43: 319-341.https://doi.org/10.4093/dmj.2018.0060
5. Zhao XB, Ren GS (2016) Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine 95.https://doi.org/10.1097/MD.0000000000005602
6. Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol 14: 89-103.https://doi.org/10.5114/pg.2018.81072
7. Stelzl A, Aziz F, Riedl JM, Posch F, Smolle MA, et al. (2020) Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients. Sci Rep 10: 1-9.https://doi.org/10.1038/s41598-020-69237-y
8. Gong YW, Benjuan YL, Weijuan (2015) Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: A meta-analysis of observational studies. Oral Oncol 51: 332-340.https://doi.org/10.1016/j.oraloncology.2015.01.003
9. Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191-197.https://doi.org/10.1055/s-0029-1242458
10. Zhu B, Wu X, Wu B, Pei D, Zhang L, et al. (2017) The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PloS One 12: e0176068.https://doi.org/10.1371/journal.pone.0176068
11. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, et al. (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 13: 915-919.
12. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160-1167.https://doi.org/10.1093/aje/kwh161
13. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, et al. (1999) IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83: 15-17.https://doi.org/10.1002/(sici)1097-0215(19990924)83:1<15::aid-ijc4>3.0.co;2-y
14. Larsson SC, Giovannucci E, Wolk A (2005) Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 28: 1805-1807.https://doi.org/10.2337/diacare.28.7.1805
15. Schulze MB, Hu FB (2005) Primary prevention of diabetes: what can be done and how

much can be prevented? Annu Rev Public Health 26: 445-467.https://doi.org/10.1146/annurev.publhealth.26.021304.144532

16. Saraei P, Asadi I, Kakar MA, Moradi-Kor N (2019) The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res11:3295-3313.https://doi.org/10.2147/CMAR.S200059

17. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, et al. (2011) Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34: 2323-2328.https://doi.org/10.2337/dc11-0512

18. Kasznicki J, Sliwinska A, Drzewoski J (2014) Metformin in cancer prevention and therapy. Ann Transl Med 2: 57.https://doi.org/10.3978/j.issn.2305-5839.2014.06.01

19. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685.https://doi.org/10.2337/dc10-0666

20. Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G (2013) Diabetes mellitus and colorectal cancer prognosis: A meta-analysis. Dis Colon Rectum 56: 1304-1319. https://doi.org/10.1097/DCR.0b013e3182a479f9

21. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, et al. (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326.https://doi.org/10.2337/dc09-1380

22. Haist RE, Campbell J, Best CH (1940) The prevention of diabetes. N Eng J Med 223: 607-615.https://doi.org/10.1056/NEJM194010172231601

23. Lecarpentier Y, Claes V, Vallée A, Hébert J (2017) Interactions between PPAR gamma and the canonical Wnt/Beta-Catenin pathway in type 2 diabetes and colon cancer. PPAR Res 2017: 5879090.https://doi.org/10.1155/2017/5879090

24. Vernieri C, Galli F, Laura F, Sara L (2019) Impact of metformin use and diabetic status during adjuvant fluoropyrimidine-oxaliplatin chemotherapy on the outcome of patients with resected colon cancer: A TOSCA study subanalysis. Oncologist 24: 385-393.https://doi.org/10.1634/theoncologist.2018-0442

25. González N, Prieto I, del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, et al. (2017) 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget 8: 18456-18485.https://doi.org/10.18632/oncotarget.14472

26. Piper MS, Saad RJ (2017) Diabetes mellitus and the colon. Curr Treat Options Gastroenterol 15: 460-474.https://doi.org/10.1007/s11938-017-0151-1